col-144 and Migraine-without-Aura

Determine whether common migraine comorbidities affect the efficacy and safety of lasmiditan, a 5-HT. Across all the Comorbidity Groups, with the potential exception of fatigue, treatment-by-subgroup interaction analyses did not provide evidence of a lasmiditan-driven lasmiditan versus placebo differential treatment effect dependent on Yes versus No comorbidity subgroup for either efficacy or TEAE assessments.. The efficacy and safety of lasmiditan for treatment of individual migraine attacks appear to be independent of comorbid conditions.

Topics: Adult; Benzamides; Comorbidity; Dizziness; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine without Aura; Nausea; Piperidines; Pyridines; Serotonin Receptor Agonists; Treatment Outcome; Vertigo